エピソード

  • LLY Today - Aug 13: Lawsuits Weigh on Stock

    LLY Today - Aug 13: Lawsuits Weigh on Stock
    2026/08/13
    Hey there! It’s Joey here, your go-to guy for stock talk. I’ve been in the investing game for a while, and today, we’re looking at Eli Lilly, or LLY for short. Today was a bit of a rough one for them—stock dipped just a tiny bit, down 0.03%. Not a huge drop, but still a red day.

    So, what’s the deal? Eli Lilly had some news that didn’t sit well with investors. They’ve got ongoing lawsuits related to their obesity drug, Retatrutide, which is causing some worries for folks who are keeping an eye on the stock. People hit the sell button pretty quickly when they heard about it. You know how it goes—lawsuits can freak investors out, and this one seems to be doing just that.

    Now, on the flip side, there was some chatter about how Eli Lilly is still a strong company, and their market share is looking good. Like, they’re making moves to grab access to new markets, which could mean more customers down the line. But that lawsuit news definitely overshadowed the positives today.

    And speaking of the competition, Novo Nordisk’s CEO is out there defending their lawsuit against Eli Lilly, saying competition needs to be fair. Seems like there’s a lot of back-and-forth going on in the obesity drug space. It’s wild—these companies are really going at it, trying to stake their claim.

    One quick thing to keep in mind: Eli Lilly is still being watched closely by analysts, even with the stock slipping a bit. They’re considered one of the top stocks in the IBD 50, so there’s still a lot of interest in how they’ll perform moving forward.

    Alright, that’s a wrap for today! Just remember, this is all for fun and info—no buy or sell advice here. Thanks for tuning in, and catch you next time!
    続きを読む 一部表示
    2 分
  • LLY Today - Aug 12: Weight Loss Pill Approval

    LLY Today - Aug 12: Weight Loss Pill Approval
    2026/08/12
    Hey there! It’s Joey here, your friendly neighborhood investor, breaking down today’s market action. We’re talking about Eli Lilly, and today was a red day for them, down just about 0.81%.

    So, what went down? The stock slipped a bit, and it wasn’t a huge surprise. It seems like investors were feeling a little jittery today. There were some mixed signals in the market, and Eli Lilly didn’t exactly stand out among its peers. It’s like they were just kind of there while others were making moves.

    Now, why’d this happen? Well, part of the chatter was about their weight loss pill snagging its first approval in Europe. That’s a win, right? But instead of rallying off that good news, the stock still took a hit. It looks like broader market pressures, like oil prices dragging things down, played a role too. So, while there’s positive momentum with that approval, it wasn’t enough to keep the stock from getting a little beat up today.

    Also, there’s been some buzz from analysts after Eli Lilly's recent Q2 earnings call. They had some tough questions, and it seems like investors are still digesting what that all means for the company moving forward. So, yeah, it’s a bit of a mixed bag right now.

    Looking ahead, Eli Lilly’s got their eyes on growth, especially with their new weight loss pill making waves in Europe. That’s something to keep an eye on as they push for more approvals and market expansions.

    Alright, that’s a wrap for today! Just remember, I’m here to share info and keep it fun, but this isn’t financial advice. Catch you later, and happy investing!
    続きを読む 一部表示
    1 分
  • LLY Today - Aug 11: Earnings Anticipation

    LLY Today - Aug 11: Earnings Anticipation
    2026/08/11
    Hey there! It’s Joey here, your friendly neighborhood investor. Just hanging out, breaking down the day for you. Today we're talking about Eli Lilly, and it was a bit of a red day for them. The stock dipped about 1%—not huge, but still a bummer.

    So, what went down? Well, LLY started the day with some solid energy, but as the hours rolled on, it got a bit of a slow bleed. People were probably feeling the jitters ahead of earnings coming up soon. You know how that goes—everyone gets a little anxious when big numbers are about to drop.

    Now, let’s chat about the why. Analysts have been buzzing about Eli Lilly lately, especially with the whole GLP-1 market thing. There’s been some chatter about how their drugs are really changing the game. Some analysts even bumped up their fair value estimates for the stock. But still, with earnings around the corner, folks are a little cautious, and that makes sense. Nobody wants to get burned if things don’t pan out as expected.

    And speaking of the horizon, the buzz is that Eli Lilly's next big move could be about a new pill they’re working on. Yeah, they’re not just sticking to injections anymore. That could be a game changer for them, so keep your ears open for updates on that front.

    Alright, that’s the scoop for today! Just remember, I'm here to keep you informed and entertained, but this isn’t financial advice. Stay curious and keep that investing spirit alive! Catch you later!
    続きを読む 一部表示
    1 分
  • LLY Today - Aug 10: Earnings Buzz and Upgrades

    LLY Today - Aug 10: Earnings Buzz and Upgrades
    2026/08/10
    Hey there! It's Joey, your friendly investor buddy, here to break down the day for Eli Lilly, or LLY for short. Today was a green day for them, up about 2.14%. Not too shabby!

    So, what went down? LLY saw a nice little bump in its stock price today. You know how it goes, a lot of chatter around earnings coming up, and people are getting excited. That anticipation can really get the momentum going.

    Now, let’s talk about why this happened. There’s a lot of buzz surrounding Eli Lilly right now. A few articles are floating around, suggesting that the stock is kind of in a sweet spot. Some folks are saying it’s a buy, while others are just feeling good about its growth potential. Plus, there’s been some chatter about upgrades from analysts, which usually gets investors feeling warm and fuzzy. You know, when the big dogs say nice things, it tends to make people more optimistic.

    Also, I saw some talk about LLY being part of that elite group of stocks that are just holding strong, like Nvidia and Disney. So, there's definitely some love for Lilly in the air. But hey, it’s not all sunshine and rainbows; some people are wondering if it’s a good time to sell or just hold tight. That uncertainty can make folks hit that sell button pretty fast!

    On top of that, we’ve got earnings coming up soon, and that’s always a big deal. Investors are looking to see if Eli Lilly can keep up its high growth momentum. It’s like waiting for that big test result, right? Everyone’s on the edge of their seats.

    So, to wrap it up, Eli Lilly had a solid day, riding the wave of some positive analyst talk and the excitement around their upcoming earnings. Always nice to see a stock on the up and up.

    Remember, this is just a friendly chat about the stock market, not financial advice. Keep doing your own research, and I’ll catch you later!
    続きを読む 一部表示
    2 分
  • LLY Today - Aug 09: Mixed Signals for Eli Lilly

    LLY Today - Aug 09: Mixed Signals for Eli Lilly
    2026/08/09
    Hey there! It’s Joey here, your friendly neighborhood investor. Let’s break down what went down with Eli Lilly today. Spoiler alert: it was a red day for LLY. It slipped about half a percent.

    So, here's the scoop: the stock got hit with a little bit of selling pressure today. It opened up, looked promising for a hot minute, but then it kinda fizzled out. We saw some action, but it didn’t really pop like everyone hoped.

    Now, why the dip? Well, a lot of chatter around the GLP-1 market is stirring things up. There’s buzz about how Eli Lilly stacks up against competitors like Viking Therapeutics. Some folks are weighing their options, and when you see a good competitor in the ring, it can make investors a bit twitchy. Plus, there’s talk about how traders are eyeing the stock after earnings, and it seems like there’s a mixed bag of expectations floating around. So, yeah, that one stung a bit for investors who were hoping for a smoother ride.

    On a brighter note, Eli Lilly is gearing up for a big FDA filing for Retatrutide. That could be a game changer if all goes well. It’s got potential to shake things up and maybe, just maybe, get some good vibes back into the stock.

    To wrap it up, LLY had a bit of a rough day, but there are still some exciting things on the horizon. Just remember, I’m here for the info and fun, not to tell you what to do with your money. Stay smart and keep those vibes high! Catch you later!
    続きを読む 一部表示
    1 分
  • LLY Today - Aug 08: Slight Dip Amidst Mixed News

    LLY Today - Aug 08: Slight Dip Amidst Mixed News
    2026/08/08
    Hey there! It’s Joey, your friendly investor here. I’ve been in the game for a while, and today we’re talking about Eli Lilly, or LLY for short. It was a bit of a red day, down just a smidge, like half a percent. Not a huge drop, but still, it got a little smoked.

    So, what went down? The stock dipped about six bucks, closing around 1185. Not exactly a wild ride, but you know how it goes. Sometimes stocks just sort of chill, and today was one of those days for Lilly.

    Now, why did this happen? Well, there’s a mix of stuff going on. First off, Truist decided to raise their price target for Lilly, which is usually a good sign, right? But then you had some folks selling off shares, like Rockland Trust Co. unloading over two thousand shares. That can definitely shake things up a bit. Plus, there’s chatter about how the stock's been priced as if it's got two different futures ahead of it. That’s a little confusing, but hey, that’s the market for ya.

    Now, here’s something to keep on your radar: Eli Lilly's been getting a lot of attention for its incretin products. Those are the drugs that help manage blood sugar levels, and they’re pretty popular. So even if today was a bit slow, their future looks promising.

    To wrap it up, Eli Lilly had a quiet day, but there’s still a lot of buzz around it. Just remember, I’m here to give you the scoop, not to tell you what to do with your cash. Keep it chill and informed, and I’ll catch you later!
    続きを読む 一部表示
    1 分
  • LLY Today - Aug 07: Eli Lilly's GLP-1 Sales Boost

    LLY Today - Aug 07: Eli Lilly's GLP-1 Sales Boost
    2026/08/07
    Hey there! It’s Joey, your friendly neighborhood investor. I’ve been around the block a few times, and today I’m breaking down Eli Lilly, or LLY, for August 7th. Spoiler alert: it was a green day, just barely, up 0.05%.

    So, what went down? Honestly, not a ton of movement. The stock barely budged, but it’s still hanging in there. Volume was steady, which is kind of a good sign that folks are still interested, even if the price didn’t jump through the roof.

    Now, here’s the juicy part on why it moved a bit. Eli Lilly is riding high on the success of their GLP-1 drugs, which are doing really well. There’s some chatter about how they’re pulling ahead of Novo Nordisk in this space, and that’s got investors feeling a little more optimistic. Plus, Truist just raised their price target, which adds a nice sprinkle of confidence in the mix. People are starting to see Eli Lilly as a solid player in the pharma game, especially with all the buzz around their incretin drugs.

    And there’s something to keep in mind going forward—earnings reports are coming up. That could shake things up a bit, so keep an ear to the ground on that front.

    So, that’s the scoop on Eli Lilly today! Just a tiny bump in the road, but hey, every little bit counts, right? Remember, this is just a rundown and not financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • LLY Today - Aug 06: GLP-1 Sales Boost

    LLY Today - Aug 06: GLP-1 Sales Boost
    2026/08/06
    Hey there! It’s Joey, your friendly neighborhood investor. I’ve been doing this for a while, and today I’m breaking down Eli Lilly, ticker LLY. Spoiler alert: it was a green day, up about 1.7%.

    So, here’s the scoop. LLY climbed today, and it wasn’t just a small bump. The stock got a nice lift, thanks to some solid news about their GLP-1 drugs. These are the ones that help with weight loss and diabetes, and they’re really starting to take off. Analysts are buzzing about how these sales are widening Lilly's lead over competitors, especially Novo. That’s a big deal, right?

    Now, why did this happen? Well, a couple of things came into play. First off, there was some fresh data from a conference about their obesity drug, and it looks promising. That got investors feeling good. Plus, analysts were super optimistic, even bumping up their price targets for Lilly after they reported better-than-expected earnings recently. When the pros are excited, it often gets people hitting that buy button.

    And just a little nugget for you: the buzz around GLP-1 drugs isn’t going anywhere. With more data coming out and the market growing, Lilly seems positioned to keep riding this wave for a bit.

    So, to wrap it up, Eli Lilly had a solid day thanks to good news about their GLP-1 sales and some analyst love. Always fun to see a stock move in the right direction, right? Just remember, this is all for info and entertainment—no buy or sell advice here. Catch you later!
    続きを読む 一部表示
    1 分